230 related articles for article (PubMed ID: 36636249)
1. C-Type Lectin Receptors-Triggered Antifungal Immunity May Synergize with and Optimize the Effects of Immunotherapy in Hepatocellular Carcinoma.
Xia J; Ding H; Liu S; An R; Shi X; Chen M; Ren H
J Inflamm Res; 2023; 16():19-33. PubMed ID: 36636249
[TBL] [Abstract][Full Text] [Related]
2. Antifungal immunity mediated by C-type lectin receptors may be a novel target in immunotherapy for urothelial bladder cancer.
Li T; Liu T; Zhao Z; Pan Y; Xu X; Zhang Y; Zhan S; Zhou S; Zhu W; Guo H; Yang R
Front Immunol; 2022; 13():911325. PubMed ID: 36131933
[TBL] [Abstract][Full Text] [Related]
3. Mycobiota and C-Type Lectin Receptors in Cancers: Know thy Neighbors.
Zhang L; Chai D; Chen C; Li C; Qiu Z; Kuang T; Parveena M; Dong K; Yu J; Deng W; Wang W
Front Microbiol; 2022; 13():946995. PubMed ID: 35910636
[TBL] [Abstract][Full Text] [Related]
4. C-type lectin receptor-mediated immune recognition and response of the microbiota in the gut.
Li TH; Liu L; Hou YY; Shen SN; Wang TT
Gastroenterol Rep (Oxf); 2019 Oct; 7(5):312-321. PubMed ID: 31687150
[TBL] [Abstract][Full Text] [Related]
5. The Role of C-Type Lectin Receptor Signaling in the Intestinal Microbiota-Inflammation-Cancer Axis.
Li M; Zhang R; Li J; Li J
Front Immunol; 2022; 13():894445. PubMed ID: 35619716
[TBL] [Abstract][Full Text] [Related]
6. Role of Gut Microbiota in Hepatocarcinogenesis.
Gupta H; Youn GS; Shin MJ; Suk KT
Microorganisms; 2019 May; 7(5):. PubMed ID: 31060311
[TBL] [Abstract][Full Text] [Related]
7. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
Jiang JW; Chen XH; Ren Z; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
[TBL] [Abstract][Full Text] [Related]
8. Deletion of both Dectin-1 and Dectin-2 affects the bacterial but not fungal gut microbiota and susceptibility to colitis in mice.
Wang Y; Spatz M; Da Costa G; Michaudel C; Lapiere A; Danne C; Agus A; Michel ML; Netea MG; Langella P; Sokol H; Richard ML
Microbiome; 2022 Jun; 10(1):91. PubMed ID: 35698210
[TBL] [Abstract][Full Text] [Related]
9. C-type Lectin Receptor: Old Friend and New Player.
Hou H; Guo Y; Chang Q; Luo T; Wu X; Zhao X
Med Chem; 2017; 13(6):536-543. PubMed ID: 28494724
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma.
Zhang L; Chen C; Chai D; Li C; Qiu Z; Kuang T; Liu L; Deng W; Wang W
J Transl Med; 2023 Feb; 21(1):126. PubMed ID: 36793057
[TBL] [Abstract][Full Text] [Related]
11. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.
Das BK
APMIS; 2022 Dec; 130(12):719-740. PubMed ID: 36321381
[TBL] [Abstract][Full Text] [Related]
12. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma.
Yu Q; Wu L; Ji J; Feng J; Dai W; Li J; Wu J; Guo C
J Hepatocell Carcinoma; 2020; 7():271-288. PubMed ID: 33150145
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.
Ponziani FR; Bhoori S; Castelli C; Putignani L; Rivoltini L; Del Chierico F; Sanguinetti M; Morelli D; Paroni Sterbini F; Petito V; Reddel S; Calvani R; Camisaschi C; Picca A; Tuccitto A; Gasbarrini A; Pompili M; Mazzaferro V
Hepatology; 2019 Jan; 69(1):107-120. PubMed ID: 29665135
[TBL] [Abstract][Full Text] [Related]
14. The Gut Microbiome and Hepatocellular Carcinoma.
Akkız H
J Gastrointest Cancer; 2021 Dec; 52(4):1314-1319. PubMed ID: 34870783
[TBL] [Abstract][Full Text] [Related]
15. The protective effect of inflammatory monocytes during systemic C. albicans infection is dependent on collaboration between C-type lectin-like receptors.
Thompson A; Davies LC; Liao CT; da Fonseca DM; Griffiths JS; Andrews R; Jones AV; Clement M; Brown GD; Humphreys IR; Taylor PR; Orr SJ
PLoS Pathog; 2019 Jun; 15(6):e1007850. PubMed ID: 31242262
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage colony-stimulating factor protects mice against hepatocellular carcinoma by ameliorating intestinal dysbiosis and attenuating inflammation.
Wu YN; Zhang L; Chen T; Li X; He LH; Liu GX
World J Gastroenterol; 2020 Sep; 26(36):5420-5436. PubMed ID: 33024394
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
Schwabe RF; Greten TF
J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
[TBL] [Abstract][Full Text] [Related]
18. Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma.
Yoshikawa S; Taniguchi K; Sawamura H; Ikeda Y; Asai T; Tsuji A; Matsuda S
Explor Target Antitumor Ther; 2023; 4(4):556-568. PubMed ID: 37720344
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma.
Shen S; Khatiwada S; Behary J; Kim R; Zekry A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565229
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
